Загрузка видео...

Не удалось загрузить видео

На главную

DatoDXd is now approved for previously treated mEGFR NSCLC based off #TROPIONLung01 & 05! We had a chance to 🗣️ this trial, findings, AEs and sequencing w/ Jacob sands Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm

OncBrothers's profile picture

Oncology Brothers

21,273 subscribers

14,446 просмотров • 11 месяцев назад •via X (Twitter)

#TROPIONLung01#OncTwitter#lcsm
LIVE

Anya Rossi• Live Now

Private livecam show

Комментарии: 0

Нет доступных комментариев

Здесь появятся комментарии из оригинального поста

Похожие видео

Zongertinib is now approved for Her2+ NSCLC based off Beamion Lung-1! We had a chance to 🗣️ Her2 testing, trial, findings, AEs and sequencing w/ Joshua Sabari, MD Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm OncUpdates
1:11

Zongertinib is now approved for Her2+ NSCLC based off Beamion Lung-1! We had a chance to 🗣️ Her2 testing, trial, findings, AEs and sequencing w/ Joshua Sabari, MD Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm OncUpdates

Oncology Brothers

25,876 просмотров • 11 месяцев назад

#Cabozantinib is now approved in #NET based off #CABINET study! We discussed the design, findings, sequencing, and AEs w/ Aman Chauhan Full 🗣️: ⭐️ ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #gism #GiOnc
1:05

#Cabozantinib is now approved in #NET based off #CABINET study! We discussed the design, findings, sequencing, and AEs w/ Aman Chauhan Full 🗣️: ⭐️ ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #gism #GiOnc

Oncology Brothers

21,289 просмотров • 1 год назад

ToxCheck: AEs for ADCs approved in Lung Cancer & how to manage them with Jacob sands: ✅ TDXd: HER2+ ✅ DatoDXd: EGFR+ ✅ TelisoV: C-MET Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter OncUpdates OncoAlert #lcsm
1:28

ToxCheck: AEs for ADCs approved in Lung Cancer & how to manage them with Jacob sands: ✅ TDXd: HER2+ ✅ DatoDXd: EGFR+ ✅ TelisoV: C-MET Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter OncUpdates OncoAlert #lcsm

Oncology Brothers

15,258 просмотров • 7 месяцев назад

Lurbinectedin is now approved in 1L for ES-SCLC based off #IMForte! We had a chance to discuss the trial, findings, AE's and management w/ Isabel Preeshagul Stephen V Liu, MD & Ticiana Batista (Leal) Full 🗣️: ⭐️ ⭐️ On “Oncology Brothers” podcast #OncTwitter #lcsm
0:58

Lurbinectedin is now approved in 1L for ES-SCLC based off #IMForte! We had a chance to discuss the trial, findings, AE's and management w/ Isabel Preeshagul Stephen V Liu, MD & Ticiana Batista (Leal) Full 🗣️: ⭐️ ⭐️ On “Oncology Brothers” podcast #OncTwitter #lcsm

Oncology Brothers

15,442 просмотров • 10 месяцев назад

#GISeries: #Zolbetuximab was approved based off #GLOW & #SPOTLIGHT! We discussed the design, findings, sequencing and AEs/management w/ Kohei shitara Full Discussion: ⭐️ ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #gism
2:05

#GISeries: #Zolbetuximab was approved based off #GLOW & #SPOTLIGHT! We discussed the design, findings, sequencing and AEs/management w/ Kohei shitara Full Discussion: ⭐️ ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #gism

Oncology Brothers

28,211 просмотров • 1 год назад

Durvalumab (+FLOT) is now U.S. FDA ✅ for resectable Gastric & GEJ adenocarcinoma based off #MATTERHORN! We 🗣️ this trial, findings, PDL1, and AEs w/ Yelena Y. Janjigian MD Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast OncoAlert OncUpdates #gism
1:10

Durvalumab (+FLOT) is now U.S. FDA ✅ for resectable Gastric & GEJ adenocarcinoma based off #MATTERHORN! We 🗣️ this trial, findings, PDL1, and AEs w/ Yelena Y. Janjigian MD Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast OncoAlert OncUpdates #gism

Oncology Brothers

10,064 просмотров • 8 месяцев назад

ToxCheck: AEs for ROS1 inhibitors & how to manage them when treating ROS1 fusion positive NSCLC w/ Dr. Estela Rodriguez ✅ Crizotinib ✅ Enterectinib ✅ Repotrectinib ✅ Taletrectinib Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter OncUpdates
1:01

ToxCheck: AEs for ROS1 inhibitors & how to manage them when treating ROS1 fusion positive NSCLC w/ Dr. Estela Rodriguez ✅ Crizotinib ✅ Enterectinib ✅ Repotrectinib ✅ Taletrectinib Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter OncUpdates

Oncology Brothers

17,339 просмотров • 8 месяцев назад

ToxCheck series: Common anti-EGFR drugs we use for mEGFR non-small cell #LungCancer w/ gilberto lopes ✅ Afatinib ✅ Osimertinib ✅ Amivantamab + Lazertinib Full discussion: ⭐️ ⭐️ Also on the “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates
1:19

ToxCheck series: Common anti-EGFR drugs we use for mEGFR non-small cell #LungCancer w/ gilberto lopes ✅ Afatinib ✅ Osimertinib ✅ Amivantamab + Lazertinib Full discussion: ⭐️ ⭐️ Also on the “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates

Oncology Brothers

28,555 просмотров • 1 год назад

In our “Challenging Cases” 🗣️ we touch on 2L & beyond for RCC w/ David Braun!“What next” after dual ICI or IO+TKI? ✅ Sequencing ✅ Data post IO ✅ AEs & management Full 🗣️: ⭐️ ⭐️ “Oncology Brothers” podcast #OncTwitter #gusm OncUpdates OncoAlert
1:10

In our “Challenging Cases” 🗣️ we touch on 2L & beyond for RCC w/ David Braun!“What next” after dual ICI or IO+TKI? ✅ Sequencing ✅ Data post IO ✅ AEs & management Full 🗣️: ⭐️ ⭐️ “Oncology Brothers” podcast #OncTwitter #gusm OncUpdates OncoAlert

Oncology Brothers

10,925 просмотров • 8 месяцев назад

#ToxCheck: AntiVEGF & AntiEGFR have been approved for years. Just before #GI25, w/ Pashtoon Kasi MD, MS we 🗣️ key AEs & management strategies for these drugs! Full 📢 ⭐️ ⭐️ “Oncology Brothers” podcast #OncTwitter #bevacizumab #panitumumab #cetuximab #crcsm
1:13

#ToxCheck: AntiVEGF & AntiEGFR have been approved for years. Just before #GI25, w/ Pashtoon Kasi MD, MS we 🗣️ key AEs & management strategies for these drugs! Full 📢 ⭐️ ⭐️ “Oncology Brothers” podcast #OncTwitter #bevacizumab #panitumumab #cetuximab #crcsm

Oncology Brothers

20,720 просмотров • 1 год назад

Treatment Algorithm: Metastatic Non-Small Cell Lung cancer with 🎯 mutations in 1L w/ Eric K. Singhi, MD ✅ 1L tx options ✅ Sequencing ✅ Re-testing for mutations Full 🗣️: ⭐️ OncBrothers & OncUpdates Website ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm #MedX
1:26

Treatment Algorithm: Metastatic Non-Small Cell Lung cancer with 🎯 mutations in 1L w/ Eric K. Singhi, MD ✅ 1L tx options ✅ Sequencing ✅ Re-testing for mutations Full 🗣️: ⭐️ OncBrothers & OncUpdates Website ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm #MedX

Oncology Brothers

11,844 просмотров • 2 месяцев назад

Treatment Algorithm series: Early stage NSCLC w/ Deepa Rangachari, MD, FASCO ✅ Resectable disease ✅ Role of NGS early on ✅ Stage III unresectable disease Full discussion: ⭐️ ⭐️ Also on the “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates
1:14

Treatment Algorithm series: Early stage NSCLC w/ Deepa Rangachari, MD, FASCO ✅ Resectable disease ✅ Role of NGS early on ✅ Stage III unresectable disease Full discussion: ⭐️ ⭐️ Also on the “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates

Oncology Brothers

26,482 просмотров • 1 год назад

As we gear up for #GI26, we discussed testing and the current SoC for HER2+ advanced/metastatic GEJ/Gastric cancer with Rutika Mehta: Full discussion: ⭐️ ⭐️ ⭐️ Also on “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates
1:19

As we gear up for #GI26, we discussed testing and the current SoC for HER2+ advanced/metastatic GEJ/Gastric cancer with Rutika Mehta: Full discussion: ⭐️ ⭐️ ⭐️ Also on “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates

Oncology Brothers

11,991 просмотров • 7 месяцев назад

Lung Cancer Conference Highlights from #ASCO26 w/ Isabel Preeshagul ✅ #LIBRETTO432 ✅ #CROWN (& LORIN) ✅ #CHRYSALIS2 ✅ #HARMONi6 ✅ A quick mention about DeLLphi304 Full 🗣️ ⭐️ OncBrothers & OncUpdates website ⭐️“Oncology Brothers” podcast #OncTwitter #lcsm #MedTwitter
1:36

Lung Cancer Conference Highlights from #ASCO26 w/ Isabel Preeshagul ✅ #LIBRETTO432 ✅ #CROWN (& LORIN) ✅ #CHRYSALIS2 ✅ #HARMONi6 ✅ A quick mention about DeLLphi304 Full 🗣️ ⭐️ OncBrothers & OncUpdates website ⭐️“Oncology Brothers” podcast #OncTwitter #lcsm #MedTwitter

Oncology Brothers

15,386 просмотров • 2 месяцев назад

Signing off 2025 on a positive note w/ a discussion around U.S. FDA approval of #Enfortumab + Pembro (EV303) in MIBC w/ Tom Powles (design, findings, AEs, role of ctDNA) Full 🗣️: ⭐️ ⭐️ “Oncology Brothers” podcast #BladderCancer OncUpdates OncoAlert
1:08

Signing off 2025 on a positive note w/ a discussion around U.S. FDA approval of #Enfortumab + Pembro (EV303) in MIBC w/ Tom Powles (design, findings, AEs, role of ctDNA) Full 🗣️: ⭐️ ⭐️ “Oncology Brothers” podcast #BladderCancer OncUpdates OncoAlert

Oncology Brothers

11,998 просмотров • 7 месяцев назад

In our “Challenging Cases” 🗣️ on non-muscle invasive bladder cancer w/ Shilpa Gupta & Joshua Meeks we touched on: ✅ BCG, BCG + IO, IO alone ✅ MultiD/MedOnc role early on Full discussion: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter OncUpdates
1:21

In our “Challenging Cases” 🗣️ on non-muscle invasive bladder cancer w/ Shilpa Gupta & Joshua Meeks we touched on: ✅ BCG, BCG + IO, IO alone ✅ MultiD/MedOnc role early on Full discussion: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter OncUpdates

Oncology Brothers

13,534 просмотров • 8 месяцев назад

Part 2/3 on SCLC! Here we discuss AEs and management of our available options in Extensive Stage small cell w/ Misty Dawn Shields Full 📢 🌟 🌟 🌟Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #lcsm #CME
0:54

Part 2/3 on SCLC! Here we discuss AEs and management of our available options in Extensive Stage small cell w/ Misty Dawn Shields Full 📢 🌟 🌟 🌟Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #lcsm #CME

Oncology Brothers

17,402 просмотров • 11 месяцев назад